RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nabriva Therapeutics Stock

Nabriva Therapeutics EBIT 2024

Nabriva Therapeutics EBIT

-3.65 M USD

Ticker

NBRV

ISIN

IE00BL53QQ85

WKN

A2QKWR

In 2024, Nabriva Therapeutics's EBIT was -3.65 M USD, a -88.51% increase from the -31.8 M USD EBIT recorded in the previous year.

The Nabriva Therapeutics EBIT history

YEAREBIT (undefined USD)
2027e56.56
2026e37.19
2025e15.9
2024e-3.65
2023e-31.8
2022-51.17
2021-48.53
2020-66.13
2019-79.49
2018-114.38
2017-73.77
2016-55.05
2015-27.76
2014-10.7
201321.45

Nabriva Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nabriva Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nabriva Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nabriva Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nabriva Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nabriva Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nabriva Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nabriva Therapeutics’s growth potential.

Nabriva Therapeutics Revenue, EBIT and net profit per share

DateNabriva Therapeutics RevenueNabriva Therapeutics EBITNabriva Therapeutics Net Income
2027e191.91 M undefined56.56 M undefined815.86 M undefined
2026e167.1 M undefined37.19 M undefined553.19 M undefined
2025e136.58 M undefined15.9 M undefined244.35 M undefined
2024e105.91 M undefined-3.65 M undefined-63.8 M undefined
2023e72.19 M undefined-31.8 M undefined-594.59 M undefined
202236.94 M undefined-51.17 M undefined-57.19 M undefined
202128.9 M undefined-48.53 M undefined-49.45 M undefined
20205.03 M undefined-66.13 M undefined-69.48 M undefined
20199.48 M undefined-79.49 M undefined-82.76 M undefined
20189.66 M undefined-114.38 M undefined-114.78 M undefined
20175.32 M undefined-73.77 M undefined-74.36 M undefined
20166.48 M undefined-55.05 M undefined-54.89 M undefined
20153.77 M undefined-27.76 M undefined-46.96 M undefined
20142.4 M undefined-10.7 M undefined-14.22 M undefined
20130 undefined21.45 M undefined14.88 M undefined

Nabriva Therapeutics stock margins

The Nabriva Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nabriva Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nabriva Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nabriva Therapeutics's sales revenue. A higher gross margin percentage indicates that the Nabriva Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nabriva Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nabriva Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nabriva Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nabriva Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nabriva Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nabriva Therapeutics Margin History

Nabriva Therapeutics Gross marginNabriva Therapeutics Profit marginNabriva Therapeutics EBIT marginNabriva Therapeutics Profit margin
2027e22.62 %29.47 %425.13 %
2026e22.62 %22.26 %331.05 %
2025e22.62 %11.64 %178.91 %
2024e22.62 %-3.45 %-60.24 %
2023e22.62 %-44.06 %-823.66 %
202222.62 %-138.55 %-154.83 %
202154.5 %-167.95 %-171.14 %
202084.76 %-1,315.42 %-1,382.22 %
201999.26 %-838.5 %-873 %
201822.62 %-1,184.06 %-1,188.2 %
201722.62 %-1,386.65 %-1,397.74 %
2016-464.2 %-849.54 %-847.07 %
2015-296.82 %-736.34 %-1,245.62 %
201426.67 %-445.83 %-592.5 %
201322.62 %0 %0 %

Nabriva Therapeutics Aktienanalyse

What does Nabriva Therapeutics do?

Nabriva Therapeutics PLC is a biopharmaceutical company based in Dublin that focuses on the research, development, and marketing of antibiotics for medical needs. The company was founded in 2006 and has since become the leading provider of antibiotics for infectious diseases in Europe and the USA. Nabriva Therapeutics' business model aims to improve the production of antibiotics for acute infections and develop innovative drugs for use in clinical practice and emergency settings. It specializes in serious and life-threatening infections such as pneumonia, bacterial skin and soft tissue infections, and bacterial infections of the urinary tract. The company is divided into two business segments: antibody therapeutics and antibiotics. Antibody therapeutics stimulate the body's immune system to better fight pathogens, while antibiotics directly combat and inhibit the growth of bacteria. Nabriva Therapeutics' flagship product is the antibiotic Xenleta (Levofloxacin) for the treatment of pneumonia. Xenleta is a bactericidal antibiotic that is effective against a variety of difficult-to-treat pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus with reduced susceptibility to Vancomycin (VSSA), acting directly on bacteria. It has been reviewed and approved by the FDA. Nabriva Therapeutics has also advanced the development of Contepo (Fosfomycin) in the field of antibiotics. Contepo is a broad-spectrum antibiotic that is effective against gram-positive and gram-negative bacteria and is intended for the treatment of infectious diseases of the urinary tract. Nabriva Therapeutics has submitted a support application to the FDA for the approval of Contepo for the therapy of complicated urinary tract infections. In August 2020, Nabriva Therapeutics announced the completion of an agreement with Taiho Pharmaceutical Co., Ltd. to market Xenleta in Brazil. The company has also entered into a collaboration with Merck and Co.'s biopharmaceutical organization to investigate the potential of Xenleta for treating patients with diseases such as bacterial skin and soft tissue infections and lung infections. Overall, Nabriva Therapeutics has played an important role in the development of antibiotics for infectious diseases and the fight against antibiotic resistance. With its innovative products and collaboration with other biopharmaceutical organizations, Nabriva Therapeutics has improved its position in the industry and strengthened its leadership in the field of antibiotic therapy. Nabriva Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Nabriva Therapeutics's EBIT

Nabriva Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Nabriva Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Nabriva Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Nabriva Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Nabriva Therapeutics stock

How much did Nabriva Therapeutics achieve in EBIT for the current year?

In the current year, Nabriva Therapeutics has achieved an EBIT of -3.65 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Nabriva Therapeutics.

How has the EBIT of Nabriva Therapeutics developed in recent years?

The EBIT of Nabriva Therapeutics has increased by -88.509% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Nabriva Therapeutics?

The EBIT of Nabriva Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Nabriva Therapeutics pay?

Over the past 12 months, Nabriva Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nabriva Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nabriva Therapeutics?

The current dividend yield of Nabriva Therapeutics is .

When does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nabriva Therapeutics?

Nabriva Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Nabriva Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nabriva Therapeutics located?

Nabriva Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nabriva Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nabriva Therapeutics from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Nabriva Therapeutics pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Nabriva Therapeutics in the year 2023?

In the year 2023, Nabriva Therapeutics distributed 0 USD as dividends.

In which currency does Nabriva Therapeutics pay out the dividend?

The dividends of Nabriva Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nabriva Therapeutics

Our stock analysis for Nabriva Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nabriva Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.